

MDP System DUR SURVEY TOOL




Landing Page




PRA Disclosure Statement This mandatory information collection (section 4401 of the Omnibus Budget Reconciliation Act of 1990 and section 1927(g) of the Social Security Act) is necessary to establish patient profiles in pharmacies, identify problems in prescribing and/or dispensing, determine each program's ability to meet minimum standards required for Federal financial participation, and ensure quality pharmaceutical care for Medicaid patients. State Medicaid agencies that have prescription drug programs are required to perform prospective and retrospective DUR in order to identify aberrations in prescribing, dispensing and/or patient behavior. Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The control number for this information collection request is 0938-0659 (Expires: TBD). Public burden for all of the collection of information requirements under this control number is estimated at 64 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.


Assign DUR State Role



Assign State DUR Designee Survey Sections



Assign DUR State Designee



MDP System - DUR FFS

Drug Utilization Review



Federal Fiscal Year 2018 DUR Surveys

Reporting Period: October 1, 2017 to September 30, 2018

	Survey Type	Status	Medicaid MCO Name	Due Date	Action
1	FFS	Pending	N/A	6/30/2019	Select Download Add/View Comments Submit to CMS

ADD NEW MCO SURVEY



For questions about the DUR Annual Report, please contact CMS at DURPolicy@cms.hhs.gov.

Survey Disclamer

About the Survey

Fee-For-Service DUR Annual Survey

- I. Demographic Information
- II. Prospective DUR (ProDUR)
- III. Retrospective DUR (RetroDUR)
- IV. DUR Board Activity
- V. Physician Administered Drugs
- VI. Generic Policy and Utilization Data
- VII. Program Evaluation / Cost Savings / Cost Avoidance
- VIII. Fraud, Waste, and Abuse Detection
- IX. Innovative Practices
- X. E-Prescribing
- XI. Managed Care Organizations (MCOs)
- XII. Executive Summary

FFY 2018 MARYLAND FEE-FOR-SERVICE DUR ANNUAL SURVEY

About the Survey

Section 1927 (g) (3) (D) of the Social Security Act (the Act) requires each State to submit an annual report on the operation of its Medicaid Drug Utilization Review (DUR) program. Such reports are to include: descriptions of the nature and scope of the prospective and retrospective DUR programs; a summary of the interventions used in retrospective DUR and an assessment of the education program; a description of DUR Board activities; and an assessment of the DUR program's impact on quality of care as well as any cost savings generated by the program.

This report covers the period October 1, 2017 to September 30, 2018 and is **due for submission to**CMS Central Office by no later than June 30, 2019. Answering the attached questions and returning the requested materials as attachments to the report will constitute compliance with the above-mentioned statutory requirement.

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid O.M.B. control number. The valid O.M.B. control number for this information collection is 0938-0659. The time required to complete this information collection is estimated to average 32 hours per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.


I have read the information about this survey.

CONTINUE

Demographic Information

About the Survey		FFY 2018 MARYLAND FEE-FOR-SERVICE DUR ANNUAL SURVEY					
	-For-Service DUR Annual	Demographic Information					
l.	Demographic Information	Medicaid Agency information					
II. III.	Prospective DUR (ProDUR) Retrospective DUR (RetroDUR)	Identify state person responsible for DUR Annual Report Preparation.					
IV.	DUR Board Activity	First Name					
V.	Physician Administered Drugs						
VI.	Generic Policy and Utilization Data	Last Name					
VII.	Program Evaluation / Cost Savings / Cost Avoidance	Email Address					
VIII.	Fraud, Waste, and Abuse Detection						
IX.	Innovative Practices						
Χ.	E-Prescribing	Area Code/Phone Number					
XI.	Managed Care Organizations (MCOs)	AAA-AAAA					
XII.	Executive Summary	On average, how many beneficiaries are enrolled in your state's Medicair program that have a pharmacy benefit? beneficiaries					
		plan(s)? beneficiaries					
		CLEAR SAVE CERTIFY					
		Exit Pr	evious Next				

Section




E-prescribing

About the Survey		FFY 2018 MARYLAND FEE-FOR-SERVICE DUR ANNUAL SURVEY					
Fee-For-Service DUR Annual Survey		E-Prescribing	₽ PRINT				
II. F III. F (()	Prospective DUR (ProDUR) Retrospective DUR (ProDUR) Retrospective DUR RetroDUR) DUR Board Activity Physician Administered Drugs Generic Policy and Utilization Data Program Evaluation / Cost Savings / Cost Avoidance Fraud, Waste, and Abuse Detection	1. Does your MMIS or pharmacy vendor have a portal to electronically provide patient did data and pharmacy coverage limitations to a prescriber prior to prescribing upon inquives. Yes No 2. Does your system use the NCPDP Origin Code that indicates the prescription source? Yes No CLEAR SAVE CERTIFY	-				
	nnovative Practices E-Prescribing	Exit Previous	Next				
	Managed Care Organizations (MCOs)						
XII. E	Executive Summary						

Innovative Practices

FFY 2018 MARYLAND FEE-FOR-SERVICE DUR ANNUAL SURVEY About the Survey **Innovative Practices** PRINT Fee-For-Service DUR Annual Survey I. Demographic Information Attachment 6 - Innovative Practices Narrative II. Prospective DUR (ProDUR) Have you developed any innovative practices during the past year (i.e. Substance Use Disorder, III. Retrospective DUR (RetroDUR) Hepatitis C, Cystic Fibrosis, MEDD, Value Based Purchasing)? Please describe in detailed narrative form any innovative practices that you believe have improved the administration of your DUR IV. DUR Board Activity program, the appropriateness of prescription drug use and/or have helped to control costs (i.e., disease management, academic detailing, automated prior authorizations, continuing education V. Physician Administered Drugs programs). VI. Generic Policy and Does the state have Attachment 6 described above to upload? Utilization Data O Yes VII. Program Evaluation / Cost Savings / Cost Avoidance O No VIII. Fraud, Waste, and Abuse Detection **CERTIFY** IX. Innovative Practices X. E-Prescribing XI. Managed Care Organizations (MCOs) Exit **Previous** Next XII. Executive Summary

Executive Summary



MDP System - DUR (FFS)

Drug Utilization Review



Federal Fiscal Year 2018 DUR Surveys

Colorado Fee-For-Service Survey

State DUR Technical Contact:

John Vestergaard Hau

ASSIGN SECTION(S) TO DESIGNEE(S)

Section	Title	Designee	Completed	State Certified	Action
1	Demographic Information	Jack Smith	~	~	Select
II	Prospective DUR (ProDUR)	Jack Smith	~	***	Select
III	Retrospective DUR (RetroDUR)	Armin Gips	~	•••	Select
IV	DUR Board Activity	Mira Belle	~	•••	Select
V	Physician Administered Drugs	Ramon Alf Peterson	***		Select
VI	Generic Policy and Utilization Data	Ramon Alf Peterson	~	~	Select
VII	Program Evaluation / Cost Savings / Cost Avoidance	Jack Smith	~	~	Select
VIII	Fraud, Waste, and Abuse Detection	Mira Belle Nässe	~	•••	Select
IX	Innovative Practices	-	~	•••	Select
х	E-Prescribing	Klaus Thaler	~	~	Select
XI	Managed Care Organizations (MCOs)	Bill Yard	~	***	Select
XII	Executive Summary	-	***		Select

MDP System - Dashboard

Drug Utilization Review




Federal Fiscal Year 2018 DUR Surveys

Reporting Period: October 1, 2017 to September 30, 2018


	Survey Type	Status	Medicaid MCO Name	Due Date	Action
1	FFS	Pending	N/A	6/30/2019	Select Download Add/View Comments Submit to CMS
2	MCO	Pending	Rocky Mountain Health Plans	6/30/2019	Select Download Add/View Comments Submit to CMS
3	MCO	Available	Denver Health Choice Plans	6/30/2019	Select Download Add/View Comments Submit to CMS

ADD NEW MCO SURVEY

MDP System - DUR MCO



MDP System - DUR MCO (Con't)



MDP System - DUR MCO Completed Survey

Drug Utilization Review



Federal Fiscal Year 2018 DUR Surveys

Colorado MCO Survey

Rocky Mountain Health Plans

State DUR Technical Contact:

John Vestergaard Hau

Designee:

Assign

Survey Responses	Upload Date	Completed	State Certified	Action
MCO Survey	-	***		Upload Certify
Attachment 1 – Retrospective Educational Outreach Summary	-	***		Upload Certify
Attachment 2 – Summary of DUR Board Activities	-	***		Upload Certify
Attachment 3 – Generic Drug Substitution Policies	-	***		Upload Certify
Attachment 4 – Innovative Practices	-	***		Upload Certify
Attachment 5 – E-Prescribing Activity Summary	-	• • • •		Upload Certify
Attachment 6 – Executive Summary	-	***		Upload Certify

Back to DUR Home